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Eculizumab for Gemcitabine-Induced Hemolytic 
Uremic Syndrome: A Novel Therapy for an 
Emerging Condition
Raphael Karkowsky, MD and Kinjal Parikh, MD 
InTroduCTIon
Atypical hemolytic uremic syndrome (aHUS), a 
thrombotic microangiopathy (TMA), is a disease 
characterized by hemolytic anemia, thrombocytopenia, 
and renal impairment. Gemcitabine, a commonly used 
chemotherapy, is emerging as a cause of aHUS.  Although 
rare, the morbidity and mortality can be significant. 
Few studies have explored the use of eculizumab, an 
anti-C5 monoclonal antibody as a potential therapy for 
gemcitabine-induced aHUS.
CaSE PrESEnTaTIon
A 45 year old Caucasian male with metastatic urothelial 
carcinoma was started on weekly gemcitabine (1000 
mg/m2 per dose) to treat recurrent disease. During his 
seventh cycle, he was hospitalized for hypertension, 
acute kidney injury, and anemia.  Laboratory data at 
that time revealed a hemoglobin of 6.2 g/dL (reference 
range 14.0-17.0 g/dL) and a platelet count of 70 x 109/L 
(reference range 140-400x 109/L).  Hemolysis was 
suggested by an elevated lactate dehydrogenase (LDH) 
of 420 IU/L (reference range 125-240 IU/L), undetectable 
haptoglobin, and the presence of schistocytes on the 
peripheral smear (see Figure 1). Creatinine was elevated 
to 2.8 mg/dL (reference range 0.7-1.4 mg/dL) and an 
ADAMTS-13 (A disintegrin and metalloproteinase with a 
thromboSpondin type 1 motif, member 13) returned as 
normal. The patient was diagnosed with gemcitabine-
induced aHUS. Gemcitabine was discontinued, and 
the patient was started on steroids. Two weeks later, 
he presented with generalized tonic-clonic seizures, 
uncontrolled hypertension, and worsening renal failure. 
His labs on admission showed continued hemolysis and 
thrombocytopenia. In light of the patient’s poor response 
to steroids, the decision was made to start eculizumab.  
dIFFErEnTIal dIagnoSIS
Gemcitabine-induced aHUS is often a difficult diagnosis 
to make. In this case, it was distinguished from thrombotic 
thrombocytopenic purpura (TTP) by normal levels of 
ADAMTS-13. Furthermore, normal coagulation studies 
and the lack of bleeding made disseminated intravascular 
Figure 1. Microscopic appearance of peripheral blood smear from 
patient (×100), showing increased schistocytes, echinocytes, and 
acanthocytes
Figure 2. Microscopic appearance of bone marrow biopsy from 
patient (×20), showing hypercellular bone marrow with trilineage 
hematopoiesis and no evidence of dysplasia or metastatic disease
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coagulation unlikely.  Bone marrow biopsy showed 
trilineage, hypercellular hematopoiesis, suggesting 
peripheral destruction rather than myelosuppression 
from chemotherapy (see Figure 2). Idiopathic thrombo-
cytopenic purpura was a less likely diagnosis, as the 
presence of schistocytes suggested microangiopathy.   
ouTCoME and Follow-uP
The patient was started on eculizumab and received a 
course of six doses. His treatment was complicated by 
a multifocal pneumonia that developed four days after 
receiving his second dose. His labs two months after 
starting treatment showed an improved platelet count 
of 118 x 109/L.  Although he remained anemic, his labs 
did not show evidence of further hemolysis (see figure 
3). The patient’s creatinine remained elevated at 6.2 mg/
dL, and he was started on renal replacement therapy 
(RRT). The patient died three months after initiation of 
eculizumab therapy secondary to complications of his 
underlying malignancy.
dISCuSSIon
The vast majority of HUS are preceded by a bout of 
infectious diarrhea, usually due to Escheria coli; 90% of 
cases are not, and are therefore termed atypical.1 This 
atypical form of HUS is associated with factors such as 
human immunodeficiency virus infection, malignancy, 
organ transplantation, pregnancy, or medications, 
including anti-neoplastic drugs.1,2 Recently, gemcitabine, 
a 2`,2`-difluorodeoxycytidine,  has surfaced as a cause 
of atypical HUS. The incidence of gemcitabine-induced 
aHUS ranges from 0.015 to 1.4%2 per current case series 
reviews.  
Pathologically, aHUS is identical to the typical form. 
Histology generally shows arteriole and capillary 
thickening, a swollen endothelium, and proteinaceous 
deposits in the subendothelium.  A blood smear will 
typically show schistocytes.  The kidneys are most 
commonly involved, but the brain, lung, pancreas, 
and gastrointestinal tract may be affected as well. 
Dysregulation of the alternative complement cascade 
leads to the formation of the final membrane-attack 
complex (MAC) and subsequent endothelial injury, 
which plays a pivotal role.1 
The most agreed upon treatment for gemcitabine-
induced aHUS remains discontinuation of the drug. 
Other therapies, such as therapeutic plasma exchange 
(TPE), demonstrate less reliable effectiveness, as shown 
in a recent meta-analysis by Gore and colleagues, which 
concluded that the use of TPE is not associated with 
an improved rate of recovery.8   Recent case reports 
have also suggested a potential role for splenectomy8 or 
rituximab.7  Novel therapies such as Complement Factor 
H, a regulatory protein in the alternative complement 
Figure 3. Chart Showing response to eculizumab treatment in 
gemcitabine-induced thrombotic microangiopathy.  Red arrows 
represent eculuzimab administration and blue arrows represent 
gemcitabine administration. 
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cascade, is currently being studied as a treatment for 
patients suffering from aHUS who are deficient in this 
protein.1 
The safety of eculizumab is still being determined. In 
this case, the patient developed multifocal pneumonia 
just days after receiving his second dose of eculizumab. 
Inhibition of MAC formation by eculizumab reduces 
defense against encapsulated organisms, specifically 
those that cause pneumonia.10  Therefore, it is reasonable 
to suspect, that eculizumab may have served as a risk 
factor in our patient’s development of this complication. 
Only a few studies have investigated the treatment of 
gemcitabine-induced HUS with eculizumab.  Similar 
to the studies by Starck and colleagues and Legendre 
and colleagues, this case study highlights eculizumab’s 
effectiveness in improving microangiopathy and the 
resultant thrombocytopenia and hemolysis in aHUS. 
Those studies, although promising, were somewhat 
confounded by prior use of TPE, which was not true in 
our case. Lohr and colleagues’ case series, seemed to 
suggest that eculizumab is an effective therapy for the 
kidney damage sustained in aHUS. In our case study, 
however, the patient did not demonstrate the same 
improvement in kidney function, and his kidney disease 
ultimately progressed to the point of needing RRT. The 
role of eculuzimab in treating aHUS and its efficacy is 
still being defined.
KEy PoInTS
The above case demonstrates eculizumab’s partial 
effectiveness in treating the microangiopathy in 
gemcitabine-induced aHUS. Although the patient 
demonstrated recovery in platelet count and resolution 
of his hemolysis, he showed only limited improvement 
in renal function. Moreover, the patient’s course of 
therapy was complicated by pneumonia, which along 
with infections from other encapsulated organisms, 
may represent a possible side effect of the medication. 
Further research, specifically, larger scale prospective 
studies, are needed to better assess the degree of 
efficacy and safety of eculizumab for gemcitabine-
induced TMA.
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